ARCHIVES

Proposed Guidelines For Clinical Tests Of Oncologic Drugs

This article is from The Cancer Letter archive.

Vol. 01 No. 48 | November 28, 1975

Download PDF Visit The Full Archive

Related Articles

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003

NCI Cancer Education Program To Open To Innovative Ideas

April 2, 1993

Multivitamin Use Doesn’t Impact Outcomes, Study Finds

September 24, 2010

Review Group Report: NCI Role In Drug Development Seen As Information Provider

November 6, 1998

Racial Differences In Survival Increase According To Stage

August 31, 2007